Almost all of the examined compounds (except for 5-HT1A receptor agonists 8-OH-DPAT and 5-CT, but including agonist S14506) exhibited cytotoxic activity against neuroblastoma and prostate cancer cells. Here, HTR1A is linked to prostate carcinoma.